US business uncertainty and pricing erosion
US business remains a big unknown due to pricing erosion (~5% mid-single digit) and supply disruptions; management struggles to provide specific guidance.
GLENMARK / Q2-FY24 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Monroe facility reinspection timeline uncertain
Monroe facility remediation is largely complete, but FDA reinspection timeline is unpredictable, delaying potential revenue from the plant.
GLS divestment execution risk
The GLS divestment to Nirma is subject to regulatory and shareholder approvals; any delay could impact FY25 margin and PAT improvement plans.
India acute segment slowdown may persist
India business growth was impacted by slowdown in respiratory and dermatology; while October showed recovery, sustainability is uncertain.